RHYTHM PHARMACEUTICALS, INC.

RYTM

CIK 0001649904 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$57M
↑+36.9% +$15Mvs FY2024 (Q4)
Gross Profit
$52M
↑+37.9% +$14Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
64/100
  • Profitability
    0ROIC -82.0% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.41 (above 1.5 = solid)
  • Leverage
    64D/E 0.73 (under 0.5 = conservative)
  • Efficiency
    18Asset Turnover 0.43x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +36.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -102.6% · trend +156.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$905K
investment in PP&E
Stock-based comp (TTM)
$67M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$480M
everything owned
Total liabilities
$210M
everything owed
Stockholders' equity
$139M
shareholder claim
Net debt
$47M
LT debt minus cash

Recent performance · 41 quarters

Revenue↑+36.9% +$15M
$57M
Net Income↓-21.2% -$9M
$-53M
Free Cash Flow
$-905K
Operating Margin↑+29.3pts
-102.6%

Drill down